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Background
Amino acids such as glutamine are important for tumor
cell growth, survival and metabolism. There is renewed
interest in glutamine metabolism due to the importance of
reductive carboxylation in cancer. The amino acid trans-
porter ASCT2 (SLC1A5) mediates uptake of glutamine in
cancer cells. We have recently reported that ASCT2
expression is significantly upregulated in melanoma, and
ASCT2 inhibition significantly decreases glutamine uptake,
cell growth, cell cycle and mTORC1 pathway activation
[1]. We have previously shown that ASCT2 expression is
regulated by the androgen receptor in prostate cancer [2],
and in this current study we further examine ASCT2
expression levels in prostate cancer. Our specific aim was
to determine the impact of inhibiting ASCT2-mediated
glutamine uptake and metabolism on cell growth.
Materials and methods
We have assessed the role of ASCT2 in prostate cancer
using: (1) tissue microarray analysis of ASCT2 protein
expression in patients before and after neoadjuvant
hormone therapy, (2) cell lines (LNCaP and PC-3) and
(3) xenograft (PC-3) models in vivo. Glutamine uptake,
cell growth, cell cycle, mTORC1 pathway and glutamine
metabolism pathways were assessed using a variety of
ASCT2 inhibitors and shRNA mediated ASCT2
knockdown.
Results
ASCT2 is highly expressed in primary prostate cancer,
but levels decrease after neoadjuvant hormone therapy,
before increasing again in recurrent disease. Inhibition
of ASCT2 function by benzylserine led to decreases in
glutamine uptake, glutamine metabolism (oxygen con-
sumption rate, glutamine oxidation and lipogenesis), cell
cycle progression, mTORC1 pathway activation and cell
growth. These data were confirmed after shRNA-
mediated ASCT2 knockdown in vitro. Furthermore,
shRNA knockdown in PC-3 cell xenografts led to a sig-
nificant reduction in tumor growth in vivo.
Conclusions
ASCT2-mediated glutamine uptake is essential for multiple
pathways including glutamine metabolism and mTORC1
signaling, thereby regulating cellular energy, protein
synthesis and cell growth. As such, ASCT2 is a putative
therapeutic target in prostate cancer.
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